← FDA DRUG APPROVALS

FDA ANDA · ANDA206485

MAGNESIUM SULFATE

magnesium sulfate heptahydrate

Sponsor: FRESENIUS KABI USA

APPLICATION

ANDA206485

TYPE

ANDA

ORIGINAL APPROVAL

2016-03-15

LATEST ACTION

2016-03-15

ROUTE

INTRAVENOUS, INJECTION

DOSAGE FORM

INJECTABLE

MARKETING STATUS

Prescription

Products

MAGNESIUM SULFATE IN PLASTIC CONTAINERPrescription

MAGNESIUM SULFATE 4GM/100ML (40MG/ML) · INJECTABLE · INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINERPrescription

MAGNESIUM SULFATE 20GM/500ML (40MG/ML) · INJECTABLE · INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINERPrescription

MAGNESIUM SULFATE 4GM/50ML (80MG/ML) · INJECTABLE · INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINERPrescription

MAGNESIUM SULFATE 40GM/1000ML (40MG/ML) · INJECTABLE · INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINERPrescription

MAGNESIUM SULFATE 2GM/50ML (40MG/ML) · INJECTABLE · INJECTION

Approval history

2016-03-15UNKNOWN · Original · standardAP

VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →